The future of British healthcare: becoming a life science superpower
The link between deprivation and health outcomes is long established. Yet more than a decade since the Marmot review, a ground-breaking report on the topic, was published, the Covid pandemic has provided the starkest reminder yet of how much deprivation can influence public health – with both illness and mortality rates significantly higher in poorer communities. With the support of pharmaceutical company MSD, The Spectator brought together a panel to address the issue – in particular, whether the UK’s burgeoning life sciences industry (the research-driven sector spanning pharmaceuticals, diagnostics and digital health) might be able to help in addressing some of these longstanding inequalities.
